sameAs
Vaccines against malariaCommon NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association studyVariants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West AfricaLack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureusViral vectors as vaccine platforms: from immunogenicity to impactGenome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controlsAssociation scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsSafety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South AfricaMalaria vaccines: identifying Plasmodium falciparum liver-stage targetsProfiling the host response to malaria vaccination and malaria challengeFusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesMicroneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in miceCD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive UgandansAspects of genetic susceptibility to human infectious diseasesCISH and susceptibility to infectious diseasesFunctional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal diseaseA phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in KenyaSafety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West AfricaExternal quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceIdentification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profilingA novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicityEffect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsComparison of clinical and parasitological data from controlled human malaria infection trialsPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsPartially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Design, recruitment, and microbiological considerations in human challenge studies.HIV in Africa (Communication arising): chemokine-receptor genes and AIDS risk.Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.Identifying recent adaptations in large-scale genomic dataA naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsCD209 genetic polymorphism and tuberculosis disease.Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
P50
Q17485685-39dfe752-4058-f1d3-9bc9-a01f303800b8Q21194911-1DA54077-47D5-4707-AA9E-E61DF1FEB476Q24550940-FF3703AA-0E0D-422C-950C-3AD58681BD6DQ24562023-7C4F59B8-AD46-4761-8BE6-C135E69ABE44Q24574798-C1FD8044-A161-4707-B0D7-CDDFBE524E0DQ24628710-ADD00BA0-7269-4CA3-98CA-B873EB8F6344Q24646663-B10ABABA-40C4-4916-A78C-BAC96B2A2DA1Q24647137-547C3AF9-0FA5-46A7-AA7E-5664C0E50D9BQ26781372-944B6255-8C6E-492F-AF26-97F3C55D4BC2Q26800494-D847D4B4-0DD9-4339-97F2-A28CE3A1C0DDQ27306708-3C757B18-0124-4C66-A650-C9E93DD8E413Q27314155-B9072581-AABB-4767-A872-416F65FEE045Q27331006-857AE695-F196-44E6-AFBF-47EF660CC929Q28254005-A809C1CE-B5EA-4D8C-9882-B3592F530E0CQ28273279-4F5DFD50-7449-4671-8B48-65BD4F838327Q28282872-AC4F5843-EBBD-476B-89A8-D5B2D1994E83Q28294642-BEB2D906-798F-429E-AB28-E80B4C97E61BQ28469062-876E85B6-24AF-48AD-B81D-4437E84F3DEAQ28473318-D0E78BDD-E267-43D1-A459-639D36CF8E3DQ28538917-B4712155-2032-417F-BD15-8C6D69A01DE3Q28704543-6392719E-F5DE-4BA0-8A9E-E2B7B35A9D91Q28727030-CD250CC5-F1A5-4C3C-8406-25E24C017B9BQ28728311-2A3663FA-EDC1-47E7-99B7-C7767557372BQ28728616-256FF734-0287-473F-9D9E-5503E192EAE0Q28731894-E646BB74-3802-489B-B566-E25C7C8284A0Q28742762-7A991024-83FF-4513-9F50-FDBCDBB0CEC6Q28743564-0AEE77F7-53D8-4316-A9A0-1CF7A93202AAQ30279261-66E9B608-6007-4ADE-91AC-E26061B70090Q30330292-9F192824-6324-41CD-A9D9-74F3912B3E6DQ30408875-05302B48-985E-492A-AEEE-0C9E7F7D0769Q30414872-78B9D529-35A8-4875-A0F2-BA08A0EF6838Q30416005-66A49B48-ADE2-4F4D-9C7D-C0BC10873E43Q30427280-72C512A6-3F62-42C3-BA41-C874C86F29FAQ30497349-1C1E0128-7713-4534-AB86-EE89C101EB47Q30662529-F81D0270-857E-4155-A85C-8574E525BDBDQ31015281-9CF64AF9-CBB3-496D-BC4C-81875AD68309Q33294698-354354AC-C324-40F6-A05F-925ED3F71657Q33303660-D9C90F4D-5E3C-4F3C-BDA2-D951ADB6EB88Q33312941-2452D5C2-AFC2-49B9-97CD-053726C2A3F5Q33317265-9EE187CF-9624-483C-965F-66D0721914B0
P50
description
Director of the Jenner Institute and Professor of Human Genetics
@en
onderzoeker
@nl
name
Adrian Hill
@de
Adrian V. S. Hill
@en
Adrian V. S. Hill
@es
Adrian V. S. Hill
@nl
Adrian V. S. Hill
@sl
أدريان في. إس. هيل
@ar
type
label
Adrian Hill
@de
Adrian V. S. Hill
@en
Adrian V. S. Hill
@es
Adrian V. S. Hill
@nl
Adrian V. S. Hill
@sl
أدريان في. إس. هيل
@ar
altLabel
Adrian Hill
@en
Adrian V. S. Hill
@de
Adrian Vivian Sinton Hill
@en
prefLabel
Adrian Hill
@de
Adrian V. S. Hill
@en
Adrian V. S. Hill
@es
Adrian V. S. Hill
@nl
Adrian V. S. Hill
@sl
أدريان في. إس. هيل
@ar
P108
P69
P735
P214
P244
P106
P21
P213
0000 0001 2433 5989
P214
P244
P31
P496
0000-0003-0900-9629
P569
1958-10-09T00:00:00Z
P734
P7859
lccn-n88288011